POP-DURVA
What it tests: Short-term preoperative durvalumab for stage I triple-negative breast cancer (TNBC). First results from the phase 2 UNLOCK 14 study.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.